Literature DB >> 27032612

Vector serotype screening for use in ovine perinatal lung gene therapy.

Lauren E McClain1, Marcus G Davey1, Phillip W Zoltick1, Maria P Limberis2, Alan W Flake1, William H Peranteau3.   

Abstract

PURPOSE: Successful in utero or perinatal gene therapy for congenital lung diseases, such as cystic fibrosis and surfactant protein deficiency, requires identifying clinically relevant viral vectors that efficiently transduce airway epithelial cells. The purpose of the current preclinical large animal study was to evaluate lung epithelium transduction of adeno-associated viral (AAV) vector serotypes following intratracheal delivery.
METHODS: Six different AAV vector serotypes (AAV1, AAV5, AAV6, AAV8, AAV9, and AAVrh10) expressing the green fluorescent protein (GFP) as the transgene were injected into the right upper lobe of perinatal sheep via bronchoscopy. At 1 week, samples were harvested, analyzed by fluorescent stereomicroscopy and immunohistochemistry, and quantified using a radial grid and quantitative real-time polymerase chain reaction (qPCR).
RESULTS: Fluorescent stereomicroscopy demonstrated GFP expression in the right upper lobe following injection of all AAV serotypes assessed except AAV5. Immunohistochemistry analysis confirmed GFP expression in small- and medium-sized airways following intratracheal injection of AAV1, 6, 8, 9, and rh10. However, only AAV8 and AAVrh10 resulted in transgene expression in large airways. These results were confirmed by qPCR, yet, after 40 cycles, AAV1 did not show GFP gene amplification.
CONCLUSION: Adeno-associated viral vector serotypes 6, 8, 9, and rh10 demonstrated efficient GFP transgene expression at early time points, and AAV8 demonstrated efficient transduction of all airway sizes with high pulmonary GFP expression tested using qPCR.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV; Gene therapy; Lung; Screening; Sheep

Mesh:

Substances:

Year:  2016        PMID: 27032612      PMCID: PMC5459309          DOI: 10.1016/j.jpedsurg.2016.02.048

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  26 in total

1.  Percutaneous ultrasound-guided injection of the trachea in fetal sheep: a novel technique to target the fetal airways.

Authors:  A L David; D M Peebles; L Gregory; M Themis; T Cook; C Coutelle; C H Rodeck
Journal:  Fetal Diagn Ther       Date:  2003 Sep-Oct       Impact factor: 2.587

2.  Incorporation of adeno-associated virus in a calcium phosphate coprecipitate improves gene transfer to airway epithelia in vitro and in vivo.

Authors:  R W Walters; D Duan; J F Engelhardt; M J Welsh
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered.

Authors:  Maria P Limberis; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-22       Impact factor: 11.205

Review 4.  Gene therapy in cystic fibrosis.

Authors:  T R Flotte; B L Laube
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

Review 5.  Inherited surfactant protein-B deficiency and surfactant protein-C associated disease: clinical features and evaluation.

Authors:  Aaron Hamvas
Journal:  Semin Perinatol       Date:  2006-12       Impact factor: 3.300

6.  Widespread and efficient marker gene expression in the airway epithelia of fetal sheep after minimally invasive tracheal application of recombinant adenovirus in utero.

Authors:  D Peebles; L G Gregory; A David; M Themis; S N Waddington; H J Knapton; M Miah; T Cook; L Lawrence; M Nivsarkar; C Rodeck; C Coutelle
Journal:  Gene Ther       Date:  2004-01       Impact factor: 5.250

7.  Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis.

Authors:  L G Johnson; J C Olsen; B Sarkadi; K L Moore; R Swanstrom; R C Boucher
Journal:  Nat Genet       Date:  1992-09       Impact factor: 38.330

8.  Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Authors:  Richard B Moss; Carlos Milla; John Colombo; Frank Accurso; Pamela L Zeitlin; John P Clancy; L Terry Spencer; Joseph Pilewski; David A Waltz; Henry L Dorkin; Thomas Ferkol; Mark Pian; Bonnie Ramsey; Barrie J Carter; Dana B Martin; Alison E Heald
Journal:  Hum Gene Ther       Date:  2007-08       Impact factor: 5.695

9.  Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro.

Authors:  Maria P Limberis; Luk H Vandenberghe; Liqun Zhang; Raymond J Pickles; James M Wilson
Journal:  Mol Ther       Date:  2008-12-09       Impact factor: 11.454

10.  Exploiting ovine immunology to improve the relevance of biomedical models.

Authors:  Gary Entrican; Sean R Wattegedera; David J Griffiths
Journal:  Mol Immunol       Date:  2014-09-26       Impact factor: 4.407

View more
  3 in total

1.  Premature delivery in the domestic sow in response to in utero delivery of AAV9 to fetal piglets.

Authors:  Kelly A Rich; Christopher G Wier; Jessica Russo; Lingling Kong; Patrick L Heilman; Anthony Reynolds; Amy Knapp; Megan G Pino; Elizabeth Keckley; Lori Mattox; Raphael A Malbrue; Charlotte J Sumner; Catalin Buhimschi; Stephen J Kolb
Journal:  Gene Ther       Date:  2021-11-22       Impact factor: 4.184

2.  Induction of Immune Tolerance to Foreign Protein via Adeno-Associated Viral Vector Gene Transfer in Mid-Gestation Fetal Sheep.

Authors:  Marcus G Davey; John S Riley; Abigail Andrews; Alec Tyminski; Maria Limberis; Jennifer E Pogoriler; Emily Partridge; Aliza Olive; Holly L Hedrick; Alan W Flake; William H Peranteau
Journal:  PLoS One       Date:  2017-01-31       Impact factor: 3.240

3.  An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy.

Authors:  Gregg A Duncan; Namho Kim; Yanerys Colon-Cortes; Jason Rodriguez; Marina Mazur; Susan E Birket; Steven M Rowe; Natalie E West; Alessandra Livraghi-Butrico; Richard C Boucher; Justin Hanes; George Aslanidi; Jung Soo Suk
Journal:  Mol Ther Methods Clin Dev       Date:  2018-03-22       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.